clad-ldac-ven induction therapy in aml: insights from a phase ii trial
Published 8 months ago • 36 plays • Length 1:04Download video MP4
Download video MP3
Similar videos
-
1:42
uproleselan added to cladribine ldac for treated secondary aml: insights from a phase ib/ii study
-
2:19
cladribine ldac venetoclax alternated with azacitidine venetoclax in older patients with aml
-
2:57
promising venetoclax updates in aml: dec10-ven, clad/ldac, antifungals
-
2:38
session highlights: transforming aml treatment and building on new approaches
-
2:48
safety and efficacy of venetoclax plus ldac in treatment-naive aml patients aged ≥ 65 years
-
2:34
the evolution of the aml treatment paradigm
-
1:17
venetoclax plus azacitidine vs intensive chemotherapy induction in fit patients with aml
-
5:36
venetoclax and azacitidine in mds patients
-
0:53
an overview of optimal sequencing therapy in aml
-
6:21
decitabine and venetoclax for aml
-
3:24
pre-induction azacitidine and venetoclax to improve the bone marrow microenvironment in aml
-
1:21
intensive therapy of older aml
-
1:22
venetoclax & azacitidine for aml in 2020
-
2:02
rwd from insight-mm: duration of therapy and treatment sequencing
-
2:25
current and emerging immune therapies in al amyloidosis: updates on hbi0101 & bispecifics
-
3:25
venetoclax plus idasanutlin for r/r aml: phase i/ii trial
-
1:07
characterizing distinct mechanisms of heart failure in patients with sickle cell disease
-
6:03
quazar aml-001: oral azacitidine as maintenance therapy in aml
-
1:00
using molecular features to determine appropriate treatment strategies for patients with cll